期刊文献+

编码hGM-CSF基因的慢病毒包装及表达 被引量:2

Package and expression of lentivirus encoding human GM-CSF genes
下载PDF
导出
摘要 目的:构建编码人粒细胞巨噬细胞集落刺激因子(hGM-CSF)慢病毒载体转染小鼠结肠癌细胞CT26,建立持续高表达hGM-CSF基因的CT26细胞株。方法:采用PCR法获得hGM-CSF DNA片段,插入转移载体L166;用CaCl2法将载体L166-hGM-CSF、L205和L311共同转染到慢病毒包装细胞293T中,72 h后收集上清液。测定慢病毒的滴度;用ELISA法检测慢病毒感染后的CT26细胞上清液中hGM-CSF的表达。结果:通过酶切电泳证实重组转移载体L166-hGM-CSF含有预期的hGM-CSF片段。收集慢病毒转染CT26细胞,滴度达4.69×105IU/ml。ELISA法检测慢病毒转染的CT26细胞上清液中有hGM-CSF的表达超过2个月。终浓度15μg/ml的嘌呤霉素成功筛选出单克隆CT26细胞株。结论:收集的慢病毒能够有效的将其所携带的目的基因导入CT26细胞并使其在细胞中高效持续表达2个月以上。 Objective: To construct a lentiviral vector encoding human granulocyte-macrophage colony- stimulating factor(hGM-CSF) genes and to transfect CT26 cells in order to establish the CT26 strains which has been continuously over-expressing the hGM-CSF gene. Methods: DNA fragments of human GM-CSF were amplified by PCR and were inserted into the vector plasmid L166. The three plasmids expressing lentivirus were packaged into virus packaging cell line 293T using the CaC12 method. After 72 hours of transfection, the virus-producing cell supematant was produced. CT26 cells were transfected by lentivirus and the titration was determined. Results: The sequence of the PCR product in the recombinant plasmid was produced. The three plasmids were effectively transferred into 293T. When the CT26 cells were infected as target cells by the lentivirus supematant, the titration of lentivirus was 4.69× 10^5IU/ml, hGM-CSF was determined in the supematant of CT26 cells transfected by lentivirus, which was kept for more than two months. The transfected CT26 cells were screened by puromycin at a terminal concentration of 15 μg/ml. Conclusion: The lentivirus encoding hGM-CSF genes were successfully constructed.
作者 林阿丽 孙青
出处 《山东大学学报(医学版)》 CAS 北大核心 2007年第6期554-557,共4页 Journal of Shandong University:Health Sciences
基金 山东省科技发展计划项目(2004GG3202003)
关键词 粒细胞巨噬细胞集落刺激因子 慢病毒载体 癌症疫苗 Granulocyte-macrophage colony-stimulating factor Lentivirus vector Cancer vaccines
  • 相关文献

参考文献13

  • 1Nemunaitis J,Sterman D,Jablons D,et al.Granulocyte-macrophage colony-stim ulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer[J].Natl Cancer Inst,2004,96(4):326-331.
  • 2Kusumoto M,Omeda S,Ikubo A,et al.Phase Ⅰclinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene[J].Can cer Immunol Immunother,2001,50(7):373-381.
  • 3Munaitis J,Jahan T,Koss H,et al.Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX((R)) vaccine in advanced-stage non-small-cell lung cancer[J].Cancer Gene Ther,2006,13(6):555-562.
  • 4Salgia R,Lynch T,Skarin A,et al.Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma[J].Clin Oncol,2003,21(4):624-630.
  • 5SambrookJ RussellDW(美) 金冬雁 黎孟枫译.分子克隆实验指南[M].北京:科学出版社,2002.463-468.
  • 6Lee CT,Wu S,Ciernik IF,et al.Genetic immunotherapy of established tumor with adenovirus-murine granulocyte-macrophage colony-stimulating factor[J].Hum Gene Ther,1997,8(2):187-193.
  • 7Jaffee E,Thomas M,Huang A,et al.Enhanced immune priming with spatial distribution of paracrine cytokine vaccine[J].Immunother Emphasis Tumor Immunol,1996,19(3):176-183.
  • 8Jaffee E,Hruban R,Laheru D,et al.Novel allogeneic GM-CSF-secreting tumor vaccine for pancreatic cancer:a phase Ⅰ trial of safety and immune activation[J].Clin Oncol,2001,19(1):145-156.
  • 9Soiffer R,Hodi FS,Haluska F,et al.Vaccination with irradiated,autologous melanoma cells engineered to secret granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patie nts with metastatic melanoma[J].Clin Oncol,2003,21(17):3 343-3 350.
  • 10Shang LL,Jonathan ER,Annemarie AD,et al.Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA[J].Cancer Res,2004,64(14):4 833-4 840.

共引文献46

同被引文献27

  • 1Jemal A, Tiwari RC, Murray T, et al. Thun. 2006. Cancer statistics, 2006 [ J ]. CA Cancer J Clin, 2006,56 : 106-130.
  • 2Adams M, Navabi H, Jasani B, et al. Dendritic cell ( DC ) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly[ 1] :poly[ C (12)U] ( Ampligen R) [J]. Vaccine ,2003,21:787-790.
  • 3Nakagawa M, Kim KH, Moscicki AB. Patterns of CD8 T- cell epitopes within the human papillomavirus type 16 ( HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable [ J ]. Clin Diagn Lab Immunol,2005,12 : 1003-1005.
  • 4Kim D,Monie A,He L,et al. Role of IL-2 secreted by PADRE-specific CD4^+ T cells in enhancing E7-specific CD8^+ T-cell immune responses [ J ]. Gene Ther, 2008,15 : 677- 687.
  • 5Bellone S, El-Sahwi K, Cocco E, et al. Human papillomavirus type 16 (HPV-16) virus-like particle Ll-specific CD8+ cytotoxic T lymphucytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV- 16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutie vaccines [J]. J Virol,2009,83:6779-6789.
  • 6Benencia F, Courreges MC, Coukos G. Whole tumor antigen vaccination using dendritic cells:comparison of RNA elcetroporation and pulsing with UV-irradiated tumor cells [ J ]. J Transl Med, 2008,29,6 : 21.
  • 7Huang B, Mao CP, Peng S, e! al. Intradermal administration of DNA vaccines combining a strategy to bypass antigen proeessing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency [J]. Vaccine, 2007,25 : 7824-7831.
  • 8Zijhnans HJ, Fleuren GJ, Baelde H J, et al. Role of tumorderived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigenpresenting cells in cervical carcinoma [ J ]. Cancer, 2007, 109:556-565.
  • 9Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte macrophage colony-stimulating factor-seereting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility,and immune activation [ J ]. Clin Cancer Res, 2008,14 : 1455-1463.
  • 10Ojima T, Iwahashi M, Nakamura M, et al. Benefits of gone transduetion of granulocyte macrophage colony- stimulating factor in cancer vaccine using genetically modified dendritic cells[J], Int J Oncol,2007,31:931- 939.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部